TY - JOUR
T1 - Sarcopenia With Limited Mobility
T2 - An International Consensus
AU - Morley, John E.
AU - Abbatecola, Angela Marie
AU - Argiles, Josep M.
AU - Baracos, Vickie
AU - Bauer, Juergen
AU - Bhasin, Shalender
AU - Cederholm, Tommy
AU - Stewart Coats, Andrew J.
AU - Cummings, Steven R.
AU - Evans, William J.
AU - Fearon, Kenneth
AU - Ferrucci, Luigi
AU - Fielding, Roger A.
AU - Guralnik, Jack M.
AU - Harris, Tamara B.
AU - Inui, Akio
AU - Kalantar-Zadeh, Kamyar
AU - Kirwan, Bridget Anne
AU - Mantovani, Giovanni
AU - Muscaritoli, Maurizio
AU - Newman, Anne B.
AU - Rossi-Fanelli, Filippo
AU - Rosano, Giuseppe M C
AU - Roubenoff, Ronenn
AU - Schambelan, Morris
AU - Sokol, Gerald H.
AU - Storer, Thomas W.
AU - Vellas, Bruno
AU - von Haehling, Stephan
AU - Yeh, Shing Shing
AU - Anker, Stefan D.
PY - 2011/7
Y1 - 2011/7
N2 - A consensus conference convened by the Society of Sarcopenia, Cachexia and Wasting Disorders has concluded that " Sarcopenia, ie, reduced muscle mass, with limited mobility" should be considered an important clinical entity and that most older persons should be screened for this condition. " Sarcopenia with limited mobility" is defined as a person with muscle loss whose walking speed is equal to or less than 1 m/s or who walks less than 400 m during a 6-minute walk, and who has a lean appendicular mass corrected for height squared of 2 standard deviations or more below the mean of healthy persons between 20 and 30 years of age of the same ethnic group. The limitation in mobility should not clearly be a result of otherwise defined specific diseases of muscle, peripheral vascular disease with intermittent claudication, central and peripheral nervous system disorders, or cachexia. Clinically significant interventions are defined as an increase in the 6-minute walk of at least 50 meters or an increase of walking speed of at least 0.1 m/s.
AB - A consensus conference convened by the Society of Sarcopenia, Cachexia and Wasting Disorders has concluded that " Sarcopenia, ie, reduced muscle mass, with limited mobility" should be considered an important clinical entity and that most older persons should be screened for this condition. " Sarcopenia with limited mobility" is defined as a person with muscle loss whose walking speed is equal to or less than 1 m/s or who walks less than 400 m during a 6-minute walk, and who has a lean appendicular mass corrected for height squared of 2 standard deviations or more below the mean of healthy persons between 20 and 30 years of age of the same ethnic group. The limitation in mobility should not clearly be a result of otherwise defined specific diseases of muscle, peripheral vascular disease with intermittent claudication, central and peripheral nervous system disorders, or cachexia. Clinically significant interventions are defined as an increase in the 6-minute walk of at least 50 meters or an increase of walking speed of at least 0.1 m/s.
UR - http://www.scopus.com/inward/record.url?scp=79959617857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959617857&partnerID=8YFLogxK
U2 - 10.1016/j.jamda.2011.04.014
DO - 10.1016/j.jamda.2011.04.014
M3 - Article
C2 - 21640657
AN - SCOPUS:79959617857
SN - 1525-8610
VL - 12
SP - 403
EP - 409
JO - Journal of the American Medical Directors Association
JF - Journal of the American Medical Directors Association
IS - 6
ER -